Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

MediWound

Nasdaq:MDWD
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MDWD
Nasdaq
$42M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • MediWound has significant price volatility in the past 3 months.
MDWD Share Price and Events
7 Day Returns
2.7%
NasdaqGM:MDWD
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-69.8%
NasdaqGM:MDWD
-2%
US Pharmaceuticals
-10%
US Market
MDWD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MediWound (MDWD) 2.7% -30.9% -48.1% -69.8% -76.8% -74.8%
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • MDWD underperformed the Pharmaceuticals industry which returned -2% over the past year.
  • MDWD underperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
MDWD
Industry
5yr Volatility vs Market

Value

 Is MediWound undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MediWound to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MediWound.

NasdaqGM:MDWD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.8%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:MDWD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 6.3%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.65
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.646 (1 + (1- 23%) (5.85%))
0.782
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.8 * 6.33%)
6.8%

Discounted Cash Flow Calculation for NasdaqGM:MDWD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MediWound is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:MDWD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.8%)
2020 10.52 Est @ 68.69% 9.85
2021 15.64 Est @ 48.6% 13.71
2022 21.04 Est @ 34.54% 17.27
2023 26.24 Est @ 24.7% 20.16
2024 30.91 Est @ 17.81% 22.24
2025 34.93 Est @ 12.99% 23.53
2026 38.29 Est @ 9.62% 24.15
2027 41.06 Est @ 7.25% 24.25
2028 43.36 Est @ 5.6% 23.98
2029 45.29 Est @ 4.44% 23.45
Present value of next 10 years cash flows $202.00
NasdaqGM:MDWD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $45.29 × (1 + 1.74%) ÷ (6.8% – 1.74%)
$909.92
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $909.92 ÷ (1 + 6.8%)10
$471.12
NasdaqGM:MDWD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $202.00 + $471.12
$673.12
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $673.12 / 27.20
$24.74
NasdaqGM:MDWD Discount to Share Price
Calculation Result
Value per share (USD) From above. $24.74
Current discount Discount to share price of $1.54
= -1 x ($1.54 - $24.74) / $24.74
93.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price MediWound is available for.
Intrinsic value
>50%
Share price is $1.54 vs Future cash flow value of $24.74
Current Discount Checks
For MediWound to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • MediWound's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • MediWound's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MediWound's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MediWound's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:MDWD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $0.08
NasdaqGM:MDWD Share Price ** NasdaqGM (2020-04-07) in USD $1.54
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MediWound.

NasdaqGM:MDWD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MDWD Share Price ÷ EPS (both in USD)

= 1.54 ÷ 0.08

20.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MediWound is good value based on earnings compared to the US Pharmaceuticals industry average.
  • MediWound is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does MediWound's expected growth come at a high price?
Raw Data
NasdaqGM:MDWD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 20.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-12.8%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

NasdaqGM:MDWD PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 20.26x ÷ -12.8%

-1.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MediWound earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MediWound's assets?
Raw Data
NasdaqGM:MDWD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.56
NasdaqGM:MDWD Share Price * NasdaqGM (2020-04-07) in USD $1.54
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:MDWD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MDWD Share Price ÷ Book Value per Share (both in USD)

= 1.54 ÷ 0.56

2.76x

* Primary Listing of MediWound.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MediWound is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess MediWound's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. MediWound has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MediWound expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-12.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MediWound expected to grow at an attractive rate?
  • MediWound's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 1.7%.
Growth vs Market Checks
  • MediWound's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • MediWound's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:MDWD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:MDWD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -12.8%
NasdaqGM:MDWD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 5.4%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:MDWD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:MDWD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 40 -8 2
2023-12-31 40 0 3
2022-12-31 19 -12 3
2021-12-31 30 -7 4
2020-12-31 24 -12 4
2020-04-08
NasdaqGM:MDWD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 32 8 2
2019-09-30 27 9 12
2019-06-30 23 12 12
2019-03-31 3 -11 -5
2018-12-31 3 -12 -6
2018-09-30 3 -15 -14
2018-06-30 3 -16 -14
2018-03-31 2 -15 -15
2017-12-31 2 -16 -15
2017-09-30 2 -16 -14
2017-06-30 2 -18 -16
2017-03-31 2 -17 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MediWound's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • MediWound's revenue is expected to grow by 5.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:MDWD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from MediWound Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MDWD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.33 0.20 -0.85 2.00
2023-12-31 -0.04 0.68 -0.69 3.00
2022-12-31 -0.40 -0.12 -0.75 3.00
2021-12-31 -0.22 -0.13 -0.25 4.00
2020-12-31 -0.41 -0.34 -0.48 4.00
2020-04-08
NasdaqGM:MDWD Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 0.08
2019-09-30 0.43
2019-06-30 0.43
2019-03-31 -0.19
2018-12-31 -0.21
2018-09-30 -0.51
2018-06-30 -0.56
2018-03-31 -0.60
2017-12-31 -0.62
2017-09-30 -0.64
2017-06-30 -0.75
2017-03-31 -0.89

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MediWound will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MediWound's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MediWound has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MediWound performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MediWound's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MediWound has delivered over 20% year on year earnings growth in the past 5 years.
  • MediWound has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • MediWound has become profitable in the last year making it difficult to compare the US Pharmaceuticals industry average.
Earnings and Revenue History
MediWound's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MediWound Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MDWD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 31.79 2.07 9.31 4.97
2019-09-30 27.34 11.59 8.97 2.97
2019-06-30 23.06 11.61 8.55 2.79
2019-03-31 3.34 -5.27 8.29 4.16
2018-12-31 3.40 -5.67 7.99 4.07
2018-09-30 2.94 -13.91 7.71 5.52
2018-06-30 2.82 -14.47 8.96 4.76
2018-03-31 2.48 -14.77 9.11 4.88
2017-12-31 2.50 -14.53 9.14 5.46
2017-09-30 2.40 -14.17 9.99 5.06
2017-06-30 2.18 -16.38 10.27 6.57
2017-03-31 1.84 -19.43 11.72 7.85
2016-12-31 1.56 -18.89 12.49 7.07
2016-09-30 1.40 -24.78 13.30 8.58
2016-06-30 0.98 -22.83 13.47 7.06
2016-03-31 0.79 -19.45 13.19 5.62
2015-12-31 0.60 -21.67 13.29 6.02
2015-09-30 0.46 -20.99 12.65 5.22
2015-06-30 0.40 -22.24 13.33 5.41
2015-03-31 0.28 -24.13 13.03 5.28
2014-12-31 0.26 -18.88 13.55 5.35
2014-09-30 0.14 -12.31 10.93 4.58
2014-06-30 0.09 -9.72 8.56 4.73
2014-03-31 0.05 -6.94 6.18 4.34
2013-12-31 -8.50 3.95 3.64
2013-09-30 6.51 2.88 3.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • MediWound has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • MediWound used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • MediWound has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess MediWound's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MediWound has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MediWound's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MediWound's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MediWound is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MediWound's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MediWound's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 8.0213612963096E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MediWound Company Filings, last reported 3 months ago.

NasdaqGM:MDWD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 15.17 0.00 29.28
2019-09-30 18.32 0.00 32.68
2019-06-30 18.18 0.00 38.54
2019-03-31 5.14 0.00 21.35
2018-12-31 8.97 0.00 23.54
2018-09-30 -1.78 0.00 25.74
2018-06-30 1.03 0.00 27.00
2018-03-31 5.03 0.00 32.90
2017-12-31 9.62 0.00 36.07
2017-09-30 11.79 0.00 40.59
2017-06-30 -0.36 0.00 20.92
2017-03-31 3.78 0.00 25.23
2016-12-31 7.77 0.00 30.03
2016-09-30 8.87 0.00 33.96
2016-06-30 13.97 0.00 37.76
2016-03-31 20.56 0.00 41.59
2015-12-31 23.47 0.00 45.77
2015-09-30 30.55 0.00 49.95
2015-06-30 33.65 0.00 55.23
2015-03-31 37.15 0.00 59.43
2014-12-31 42.87 0.00 64.85
2014-09-30 48.69 0.00 69.01
2014-06-30 52.43 0.00 73.58
2014-03-31 57.31 0.00 80.57
2013-12-31 -19.80 0.00 9.55
2013-09-30 -19.31 0.00 12.17
  • MediWound's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if MediWound's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (1.8665168655637E+18%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 11.5x coverage).
X
Financial health checks
We assess MediWound's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MediWound has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MediWound's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MediWound dividends.
If you bought $2,000 of MediWound shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MediWound's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MediWound's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:MDWD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:MDWD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MediWound has not reported any payouts.
  • Unable to verify if MediWound's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MediWound's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MediWound has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MediWound's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MediWound afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MediWound has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MediWound's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sharon Malka
COMPENSATION $877,000
AGE 47
TENURE AS CEO 0.9 years
CEO Bio

Mr. Sharon Malka, C.P.A., MBA, serves as Chief Executive officer at MediWound Ltd. since May 31, 2019. Mr. Malka served as the Chief Financial & Operation Officer at MediWound Ltd since April 2007 until June 11, 2019. Mr. Malka served as a Partner at Varinace Economic Consulting Ltd., a full-service consulting firm and as a Senior Manager at Kesselman Corporate Finance, a division of PricewaterhouseCoopers Global Network (PwC). Mr. Malka's experience includes business and economic consulting for a number of public companies regarding valuations, SEC filing, feasibility studies and financial/strategic planning. Mr. Malka holds a B.Sc. in Accounting & Business Administration from the Business Management College, Israel and an MBA from Bar Ilan University, Israel. Mr. Malka is a Certified Public Accountant.

CEO Compensation
  • Sharon's compensation has increased in line with MediWound recently becoming profitable.
  • Sharon's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the MediWound management team in years:

5.7
Average Tenure
50
Average Age
  • The average tenure for the MediWound management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Sharon Malka

TITLE
Chief Executive Officer
COMPENSATION
$877K
AGE
47
TENURE
0.9 yrs

Lior Rosenberg

TITLE
Co-Founder & Chief Medical Technology Officer
COMPENSATION
$450K
AGE
73
TENURE
19.3 yrs

Carsten Henke

TITLE
Chief Commercial Officer of Europe
COMPENSATION
$348K
AGE
53
TENURE
5.5 yrs

Ety Klinger

TITLE
Chief Research & Development Officer
COMPENSATION
$410K
AGE
57
TENURE
5.9 yrs

Boaz Gur-Lavie

TITLE
Chief Financial Officer
AGE
45
TENURE
0.8 yrs

Yaron Meyer

TITLE
Executive VP
COMPENSATION
$532K
AGE
40
TENURE
6.3 yrs

Roni Solomon

TITLE
Controller
Board of Directors Tenure

Average tenure and age of the MediWound board of directors in years:

2.8
Average Tenure
58
Average Age
  • The average tenure for the MediWound board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steve Wills

TITLE
Independent Chairman of the Board of Directors
AGE
62
TENURE
2.5 yrs

Sharon Kochan

TITLE
Independent Director
AGE
51
TENURE
2.8 yrs

Ofer Gonen

TITLE
Director
AGE
45
TENURE
16.6 yrs

Vickie Driver

TITLE
Independent Director
AGE
65
TENURE
2.9 yrs

Nissim Mashiach

TITLE
Independent Director
AGE
58
TENURE
2.8 yrs

Assaf Segal

TITLE
Director
TENURE
2.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess MediWound's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MediWound has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

MediWound Ltd. (NASDAQ:MDWD): Commentary On Fundamentals

In the case of MDWD, it is a financially-healthy company with a strong track record and an optimistic growth outlook. … Flawless balance sheet and undervalued MDWD delivered a satisfying double-digit returns of 64% in the most recent year. … NasdaqGM:MDWD Past and Future Earnings, August 14th 2019 MDWD is financially robust, with ample cash on hand and short-term investments to meet upcoming liabilities.

Simply Wall St -

Introducing MediWound (NASDAQ:MDWD), The Stock That Tanked 72%

Check out our latest analysis for MediWound MediWound isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. … A Different Perspective MediWound shareholders are down 56% for the year, but the market itself is up 6.9%.

Simply Wall St -

What Percentage Of MediWound Ltd. (NASDAQ:MDWD) Shares Do Insiders Own?

Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. … See our latest analysis for MediWound NasdaqGM:MDWD Ownership Summary, June 11th 2019 What Does The Institutional Ownership Tell Us About MediWound? … We can see that MediWound does have institutional investors; and they hold 51% of the stock.

Simply Wall St -

Is MediWound Ltd.'s (NASDAQ:MDWD) CEO Salary Justified?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. … How Does Gal Cohen's Compensation Compare With Similar Sized Companies?

Simply Wall St -

If You Had Bought MediWound (NASDAQ:MDWD) Stock Three Years Ago, You'd Be Sitting On A 40% Loss, Today

(NASDAQ:MDWD) shareholders, since the share price is down 40% in the last three years, falling well short of the market return of around 47%. … MediWound isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … While its revenue increased, the share price dropped at a rate of 16% per year.

Simply Wall St -

Is MediWound Ltd.'s (NASDAQ:MDWD) CEO Overpaid Relative To Its Peers?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Gal Cohen's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below US$200m

Simply Wall St -

What Investors Should Know About MediWound Ltd's (NASDAQ:MDWD) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does MDWD's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt

Simply Wall St -

When Can We Expect A Profit From MediWound Ltd (NASDAQ:MDWD)?

The US$185.28m market-cap posted a loss in its most recent financial year of -US$14.53m and a latest trailing-twelve-month loss of -US$14.77m leading to an even wider gap between loss and breakeven … Many investors are wondering the rate at which MDWD will turn a profit, with the big question being “when will the company breakeven?” … I’ve put together a brief outline of industry analyst expectations for MDWD, its year of breakeven and its implied growth rate.

Simply Wall St -

Company Info

Description

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Details
Name: MediWound Ltd.
MDWD
Exchange: NasdaqGM
Founded: 2000
$41,892,304
27,202,795
Website: http://www.mediwound.com
Address: MediWound Ltd.
42 Hayarkon Street,
Yavne,
8122745,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MDWD Ordinary Shares Nasdaq Global Market US USD 20. Mar 2014
DB M8W Ordinary Shares Deutsche Boerse AG DE EUR 20. Mar 2014
Number of employees
Current staff
Staff numbers
74
MediWound employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 07:46
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/17
Last earnings filing: 2020/02/25
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.